About Elacestrant
Elacestrant is a prescribed medicine for the treatment of:
Strength
Tablets of 345 mg and 86 mg (3)
Recommended Dosage
Warning and precautions
Common Elacestrant side-effects
Storage and handling
Store at room temperature between 20°C to 25°C
We follow a four-step process to procure the medicines:
When importing medication, we will need the following documents from the patient:
Once we have all these documents, the Sansfro team will initiate the application process for an import license. This license is essential to ensure that we can obtain the necessary medication once it receives government approval.
No news found.
Sansfro is committed to bridging the healthcare gap. Our purpose is to bring hope and healing to patients suffering from rare diseases by linking them with life-saving treatments through our Named Patient Program. Join us in our quest for a better and healthier world.
Know More...How does Elacestrant work?
Elacestrant works by blocking the estrogen receptor (ER) in hormones that receptor-positive breast cancer cells. It aims to lower the count of the ER, leading to the inhibition of tumor growth and cancer.
What types of breast cancer is Elacestrant intended to treat?
Elacestrant is used for the treatment of hormone receptor-positive, ER-positive, HER2- negative, ESR1-mutated advanced or metastatic breast cancer.
What are the side effects associated with Elacestrant?
Common side effects that Elacestrant can cause can vary, and it’s best to consult to the doctor; however, some side effects are decreased hemoglobin, vomiting, increased ALT, reduced sodium, and increased creatinine.
Where can I find more information about Elacestrant?
For the latest information about Elacestrant, you can consult official medical sources and clinical trial databases or reach out to our Patient Support Team at (+91) 9315705373 or help@sansfro.com
Medical counselor
India, Andorra, Argentina, Australia, Austria, Azerbaijan, Bahrain, Brazil, Bulgaria, Cambodia, Canada, Chile, Colombia, Costa Rica, Croatia, Cyprus, Denmark, Dominican Republic, Estonia, Finland, France, Georgia, Germany, Ghana, Greece, Guatemala, Iraq, Ireland, Israel, Italy, Jamaica, Japan, Jordan, Kenya, Kuwait, Latvia, Lebanon, Libya, Lithuania, Malawi, Mexico, Montenegro, Nepal, Netherlands, New Zealand, Nigeria, Norway, Oman, Pakistan, Paraguay, Peru, Poland, Qatar, Romania, Saudi Arabia, Serbia, Singapore, Slovenia, Spain, Sri Lanka, Sweden, Switzerland, United Arab Emirates, United Kingdom, United States, Venezuela, Zimbabwe, Afghanistan, Albania, Algeria, American Samoa, Angola, Anguilla, Antarctica, etc.